Biomatrix (BXM) Looking Great Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ForYourEyesOnly who wrote (161)	11/2/1997 11:31:00 AM
From: John McCarthy	Read Replies (1) of 569

THC - I understand your point and logic. Synvisc has been sold in Canada (RPR) and Sweden (Roche) for about 2 years. There is NO growth built into the 98 Revenue $. This is by design. 98 revenue $ for both countries reflect my best guess at ACTUAL 97 $. To wit: Synvisc:prior to 98, revenue $ NEVER more than $1.2 mil. a qtr. With regard to (a) International sales and (b) prior year sales: (1) Please DO NOT fall into the trap of "If you build a stadium they will come." They won't. You REQUIRE marketing and sales force $. (2) Synvisc is insignificant and perhaps not even meaningful to RPR and Roche, respectively. Each company has their own focus. Lastly, if you were forecasting a 98 P&L (for anything), after enough iterations of bad changes you would come to discover the best thing to do is build out of it, as many BAD SURPRIZES as possible. From the point of License Fees on down, this is a SAFE P&L. With respect to ALL REVENUES except (AHP) this is a SAFE P&L. So there is really only 1 question mark? <g> Let's go AHP! You just spent $16.0 mil. of your shareholders monies. Regards, John McCarthy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next